Pipeline

We are advancing a robust pipeline of cell therapies programmed with multiple coordinated synthetic drug functions.

Product		Target Discovery & Validation Candidate Selection IND Enabling Early Clinical Late Clinical
Wholly Owned Programs	AB-2100	end of IND enabling phase Renal Cell Enrolling Third Dose Level Plase 1/2
	AB-3000 series	end of IND enabling phase Prostate FIH anticipated 1H'26
	AB-6000	end of IND enabling phase Undisclosed Indication
Collaboration Programs	AB-4000 series BMS	Candidate selection phase Solid Tumor
Collaboration Programs	AB-5000 series BMS	Candidate selection phase Solid Tumor

AB-2100

AB-2100 is our second program for kidney cancer, which takes the same approach as AB-1015, but targets protein antigens present in a large proportion of tumors in kidney cancer patients. We have applied additional potency enhancements with the goal to further enable tumor killing in the suppressive microenvironment, increase persistence of the cell therapy to create longer term tumor killing, and reduce exhaustion of the cell therapy after encountering the tumor.
For more information on the Phase 1 study, please go to clinicaltrials.gov (NCT06245915).

AB-3000

AB-3000 is our third program, targeted at prostate cancer, also taking a similar logic gating approach but using antigens specific for tumors in prostate cancer patients. It will deploy one additional modification compared to AB-2100, with the goal to further increase anti-tumor potency and stimulate additional anti-tumor immunity within the patient’s body.

AB-1015

For more information on the Phase 1 study, please go to clinicaltrials.gov (NCT05617755).
No further enrollment.

1. SEER Database https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676071/

Bristol Myers Squibb Collaboration

In addition to our robust pipeline of wholly-owned programs, we have partnered with Bristol Myers Squibb in a multi-program discovery collaboration to advance next-generation T-cell therapies for solid tumors. This collaboration combines our programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development. We are currently discovering and building preclinical candidates against multiple targets, and Bristol Myers Squibb can obtain an exclusive worldwide license to develop and commercialize these candidates.